SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/A961C00288C1A8BD4857C8CDE0DEBC40C68D61C3BA33F82B98180AC92A6BB3205B64F0049409BD6017C52C54D102FAB8>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/A961C00288C1A8BD4857C8CDE0DEBC40C68D61C3BA33F82B98180AC92A6BB3205B64F0049409BD6017C52C54D102FAB8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/A961C00288C1A8BD4857C8CDE0DEBC40C68D61C3BA33F82B98180AC92A6BB3205B64F0049409BD6017C52C54D102FAB8
http://www.w3.org/2000/01/rdf-schema#comment
"Silencing PMPCB increased hepatocellular carcinoma (HCC) susceptibility to sorafenib decreased tumor burden and improved survival. These results suggest contributory role of the PMPCB in sorafenib resistance."
xsd:string
http://purl.uniprot.org/uniprot/#_315DE181347EA6B2BC83BE20977AB569792843C2B9FEDF33DE5ACAEFDC6EB00E87C10DE2B5ACD23985CD37FCA759EF88
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/A961C00288C1A8BD4857C8CDE0DEBC40C68D61C3BA33F82B98180AC92A6BB3205B64F0049409BD6017C52C54D102FAB8
http://purl.uniprot.org/uniprot/G3V0E4
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A961C00288C1A8BD4857C8CDE0DEBC40C68D61C3BA33F82B98180AC92A6BB3205B64F0049409BD6017C52C54D102FAB8
http://purl.uniprot.org/uniprot/#_G3V0E4-mappedCitation-31337603
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A961C00288C1A8BD4857C8CDE0DEBC40C68D61C3BA33F82B98180AC92A6BB3205B64F0049409BD6017C52C54D102FAB8